New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
10:04 EDTABBV, GXP, NVE, STZ, PERIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Jefferies... AbbVie (ABBV) initiated with an Outperform at Wells Fargo... Great Plains Energy (GXP) initiated with a Buy at SunTrust... NV Energy (NVE) initiated with a Neutral at SunTrust... Perion Network (PERI) initiated with a Buy at Benchmark Co... Constellation Brands (STZ) initiated with a Buy at Buckingham.
News For ABBV;GXP;NVE;STZ;PERI From The Last 14 Days
Check below for free stories on ABBV;GXP;NVE;STZ;PERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
11:15 EDTABBVRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
06:10 EDTABBVFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
13:47 EDTPERISource says report of IAC bid for Perion untrue, Reuters reports
Subscribe for More Information
13:44 EDTPERISource says report of IAC bid for Perion untrue, Reuters reports
Subscribe for More Information
09:10 EDTPERIOn The Fly: Pre-market Movers
Subscribe for More Information
06:41 EDTPERIPerion Network receives takeover offer from IAC, Calcalist says
Subscribe for More Information
September 16, 2014
09:59 EDTSTZOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ACI Worldwide (ACIW) initiated with a Neutral at Sterne Agee... ADP (ADP) initiated with a Market Perform at Bernstein... ANSYS (ANSS) initiated with a Sector Perform at RBC Capital... Accenture (ACN) initiated with a Market Perform at Bernstein... Blackhawk (HAWK) initiated with a Neutral at Sterne Agee... Coca-Cola (KO) initiated with a Market Perform at Cowen... Cognizant (CTSH) initiated with an Outperform at Bernstein... Constellation Brands (STZ) initiated with a Market Perform at Cowen... Dr Pepper Snapple (DPS) initiated with a Market Perform at Cowen... GenCorp (GY) initiated with a Hold at KeyBanc... Global Payments (GPN) initiated with a Neutral at Piper Jaffray... GoPro (GPRO) initiated with a Buy at Cleveland Research... Green Dot (GDOT) initiated with a Neutral at Sterne Agee... Lionsgate (LGF) initiated with a Buy at ISI Group... MEDNAX (MD) initiated with a Neutral at SunTrust... MasterCard (MA) initiated with a Buy at Sterne Agee... Molson Coors (TAP) initiated with an Outperform at Cowen... Monster Beverage (MNST) initiated with a Market Perform at Cowen... NetSuite (N) initiated with an Outperform at RBC Capital... Oracle (ORCL) assumed with a Sector Perform at RBC Capital... PepsiCo (PEP) initiated with an Outperform at Cowen... SAP (SAP) initiated with a Sector Perform at RBC Capital... Teekay (TK) initiated with a Hold at Deutsche Bank... Tesla (TSLA) initiated with a Buy at ISI Group... Visa (V) initiated with a Buy at Sterne Agee... Western Union (WU) initiated with a Neutral at Sterne Agee... Workday (WDAY) initiated with an Outperform at RBC Capital... Yelp (YELP) initiated with a Neutral at RW Baird... Zillow (Z) initiated with an Overweight at Stephens... zulily (ZU) initiated with an Outperform at RW Baird.
September 15, 2014
16:14 EDTSTZConstellation Brands initiated with a Market Perform at Cowen
Subscribe for More Information
10:55 EDTABBVRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
September 12, 2014
09:46 EDTPERIPerion Network initiated with a Buy at Standpoint Research
Subscribe for More Information
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
September 8, 2014
12:40 EDTABBVFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
07:15 EDTABBVIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
08:52 EDTABBVInfinity Pharmaceuticals upgraded at JMP Securities
Subscribe for More Information
07:38 EDTABBVInfinity Pharmaceuticals price target raised to $21-$25 from $17-$20 at Wells Fargo
Wells Fargo increased its price target on Infinity (INFY) after the company announced a global development and commercialization oncology agreement with AbbVie (ABBV) for duvelisib. The firm thinks the financial terms of the deal are favorably for Infinity, and significantly lower the risk presented by Infinity's stock. It raised its estimate of the drug's chances of success to 75% from 65% and keeps an Outperform rating on Infinity.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use